sitefansalaran Industry News

Severe Allergic Reactions to Indian Medications Make Headlines Emergency Import of Fibrinogen Amin Afshar, Chairman of the Board of the Iranian Hemophilia Society, stated: Due to the failure to return plasma-derived products to the country, the Food and Drug Administration has come under pressure and was forced to request emergency imports of fibrinogen from India. As a result of using this imported fibrinogen from Indian warehouses, many patients have experienced respiratory disorders and severe allergic reactions. On the other hand, due to poor health oversight in pharmaceutical production in India, continuing this approach may lead to the spread of bloodborne viruses, as occurred during the 1970s and 1980s. Unfortunately, the system is dysfunctional, and certain individuals are exploiting this lack of governance and disorder. Oversight of this process falls under the Food and Drug Administration, but this organization neither monitors the plasma import process nor ensures its return to the country, and it fails to refer the involved companies to the judiciary for accountability.

در اینجا ترجمه دقیق و رسمی متن شما به انگلیسی: Policy-Making Without Regulation A Report on Changes in Medicine Prices We review a recent report by Siavash Eftekhari, in which he states: "In recent years, changes in the prices of pharmaceutical products have not followed any clear or regulated pattern. Policymakers have often adopted non-transparent and sometimes arbitrary approaches." In analyzing the price increases, a comparison of drug price trends with macroeconomic indicators, such as general inflation and currency exchange rates, shows that the rise in medicine prices has not aligned with the country’s overall economic conditions, and in some cases, has been significantly lower than expected, especially when compared to other essential goods like food. Establishing a transparent framework based on sound economic principles for drug price policy is essential. The instability in current policies has not only enabled some producers to raise prices disproportionately, but has also put more critical sectors of the pharmaceutical industry at risk.

در اینجا ترجمه دقیق و رسمی متن شما به انگلیسی: Pharmacies for Special Patients Active During Nowruz Holidays The Minister of Health stated: “We have no shortage of medicine. On-call pharmacies will operate according to schedule during the Nowruz holidays, and 24-hour pharmacies will remain fully available. Therefore, there will be no issues in providing the medications needed by the public.” He also emphasized that pharmacies supplying medications for special patients will continue their activities throughout the Nowruz period.

در اینجا ترجمه دقیق و روان متن شما به انگلیسی: Medical Malpractice and Complaints See 10% Increase! The President of the Medical Council Organization stated that 16,000 medical complaint cases are filed annually against healthcare professionals with the Medical Council. This year, we have witnessed a 10% increase in such cases, most of which are related to cosmetic procedures.

Regarding the Claim of One-Rial Coverage for Medicine Public Relations of the Social Security Organization clarified:The Social Security Organization has neither the authority nor the ability to remove or add medications to the list of drugs covered by insurance. Pharmaceutical subsidies for certain medications are paid by the government and are not related to insurance organizations. Insurance providers, including with regard to the medicine mentioned in the video—Therapeutic Multivitamin Capsules—act according to the decisions and regulations of relevant governmental bodies. The numbers 0, 1, and 2, which appear in the Social Security Organization's pharmaceutical system, are for internal organizational use only and do not represent a literal one-rial coverage. For medications not covered by basic insurance, but instead supported through the Special and Intractable Diseases Fund or the DaruYar (Medicine Assistance Program), the number 1 is displayed. The display of number 1 for a medication means that the medicine is eligible for a government subsidy or support from a special fund, not that the basic insurance covers only a negligible amount.